^
Association details:
| Biomarker: | HR positive + TP53 mutation |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Kisqali (ribociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
Published date:
08/15/2023
Excerpt:
...evaluating the efficacy and safety of ribociclib plus endocrine therapy (ET) in Asian patients with hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer….Patients with alterations in PIK3CA and TP53 at baseline had shorter median progression-free survival compared with patients with wild-type PIK3CA and TP53, 12.7 and 7.3 months vs 19.2 and 19.4 months, respectively (P = .016 and P = .0001, respectively)....Higher ctDNA levels and PIK3CA and TP53 alterations detected at baseline were associated with inferior outcomes.
Secondary therapy:
tamoxifen + goserelin acetate; letrozole; fulvestrant
DOI:
10.1186/s12916-023-03017-z
Trial ID:
